
Al-ola Abdallah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9600870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasiaâ€related changes: A single institution experience. International Journal of Laboratory Hematology, 2022,	1.3	3
2	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e212-e219.	0.4	3
3	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e220-e226.	0.4	8
4	Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple lass relapsed/refractory multiple myeloma (RRMM). European Journal of Haematology, 2021, 107, 602-608.	2.2	7
5	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leukemia Research, 2021, 110, 106714.	0.8	2
6	Palliative Care Utilization, Transfusion Burden and Symptoms for Patients with Multiple Myeloma at the End of Life. Blood, 2021, 138, 4103-4103.	1.4	0
7	SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). Blood, 2021, 138, 2740-2740.	1.4	5
8	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. Blood, 2021, 138, 162-162.	1.4	9
9	Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 1642-1642.	1.4	8
10	Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination. Blood, 2021, 138, 3804-3804.	1.4	2
11	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 207-221.	10.7	544
12	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. Biology of Blood and Marrow Transplantation, 2020, 26, 805-813.	2.0	7
13	Car-T Treatment for Hematological Malignancies. Journal of Investigative Medicine, 2020, 68, 956-964.	1.6	20
14	Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data. Blood, 2020, 136, 35-36.	1.4	14
15	Hospitalization at the End of Life in Myeloma Patients: Lessons from the National Inpatient Sample. Blood, 2020, 136, 4-5.	1.4	0
16	Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample. Blood, 2020, 136, 53-54.	1.4	5
17	A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma. Blood, 2020, 136, 10-12.	1.4	0
18	Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience. Blood, 2018, 132, 5642-5642.	1.4	3

#	Article	IF	CITATIONS
19	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. Blood, 2018, 132, 832-832.	1.4	1
20	Image Diagnosis: Splenic Infarction Associated with Oral Contraceptive Pills in a Healthy Young Woman. , 2017, 21, 16-071.		2
21	Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 0, , .	1.0	2